PTN focusing on entering the EU market through partnerships, says analyst.
Synergy protects “financial health” without the sacrifice of extra pressure on share price, says Canaccord.
Canaccord Positive on Safety Profile of Kite’s Axi-Cel
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) stock is on the downward spiral today, to the harsh, discordant clang of 12% after the biotech firm released …
Second quarter earnings for the year are due sometime around mid-August from Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Yet, for Canaccord analyst John Newman, consensus …
This is an exciting time for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) and its shareholders. The shares have gone up over 120% after the drug maker announced positive …
Yesterday, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) reported fourth-quarter financial results and reiterated the launch of Trulance (plecanatide), Synergy’s recently-approved lead drug, for treatment of chronic …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is on fire today with shares zooming up 66% in pre-market trading after the biotech firm’s drug voclosporin scored …
Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) constipation drug Trulance will compete directly with Ironwood Pharmaceuticals (NASDAQ:IRWD) and Allergan‘s (NYSE:AGN) drug Linzess, which received FDA approval this …
Canaccord analyst John Newman weighs in on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), as competitor Ironwood Pharmaceuticals (NASDAQ:IRWD) has a PDUFA date of February 9, 2017 for …
